Amol and Reena want you to understand the following:
1. When added to moderate dose statin, the IMPROVE-IT randomized trial showed that ezetimibe improved clinical outcomes in patients after acute coronary syndrome.
2. A network meta-analysis showed that no blood pressure lowering therapy improved mortality in patients with diabetes and chronic kidney disease. The combination of ACE-inhibitors and angiotensin receptor blockers was the most effective in preventing end-stage kidney disease.
Continuing Medical Education
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.
The papers
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62459-4/abstract
Good Stuff
http://www.bmj.com/content/350/bmj.h2942
